Follow Us On
Tablet
Files
Lapatinib
Strength: 250mg
Count: 150
NDC
42291-035-15
Class
Rx
Brand Name
Tykerb
Imprint Code
L250;TV
Color(s)
Yellow
Shape
Oval
Score
No Score
Case Count
NA
Inactive Ingredients
iron oxide yellow, magnesium stearate, microcrystalline cellulose, polyethylene glycol 3350, polyvinyl alcohol (part hydrolyzed), povidone, sodium starch glycolate Type A, talc, and titanium dioxide
Indications and Usage
Lapatinib tablets are indicated in combination with: * capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib tablets in combination with capecitabine. * letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib tablets in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.
